Analyzing Structure Therapeutics (NASDAQ:GPCR) & Alzamend Neuro (NASDAQ:ALZN)

Structure Therapeutics (NASDAQ:GPCR) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Structure Therapeutics and Alzamend Neuro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-30.28%	-28.21%
Alzamend Neuro	N/A	-612.26%	-255.65%

Valuation and Earnings

This table compares Structure Therapeutics and Alzamend Neuro’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$89.62 million	($0.77)	-46.60
Alzamend Neuro	N/A	N/A	-$14.88 million	($0.99)	-0.66

Structure Therapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Structure Therapeutics and Alzamend Neuro, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	0	0	6	0	3.00
Alzamend Neuro	0	0	0	0	N/A

Structure Therapeutics presently has a consensus target price of $85.71, indicating a potential upside of 138.89%. Given Structure Therapeutics’ higher possible upside, research analysts plainly believe Structure Therapeutics is more favorable than Alzamend Neuro.

Insider & Institutional Ownership

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 10.9% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Structure Therapeutics beats Alzamend Neuro on 6 of the 9 factors compared between the two stocks.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Alzamend Neuro

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.